Navigation Links
ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
Date:8/8/2008

Conference call scheduled for August 12, 2008 at 1:30 p.m. (Pacific);

simultaneous webcast at http://www.adventrx.com

SAN DIEGO, Aug. 8 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) today announced that it will host a conference call with simultaneous webcast to discuss second quarter 2008 results on Tuesday, August 12th, 2008 at 1:30 p.m. Pacific / 4:30 p.m. Eastern. Evan M. Levine, Chief Executive Officer and President, and Mark N. K. Bagnall, Chief Financial Officer and Executive Vice President, will host the conference call.

The conference call may be accessed by dialing (888) 215-7027 for domestic callers and (913) 312-0654 for international callers. The webcast will be available live via the Internet by accessing ADVENTRX's website at http://www.adventrx.com under "Investors". Replays of the webcast will be available on ADVENTRX's website for 30 days and a phone replay will be available through September 12, 2008 by dialing (888) 203-1112 and entering the pass code 8240633.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates primarily for the treatment of cancer and infectious disease. The Company seeks to improve the performance and commercial potential of existing treatments by addressing problems associated with these treatment regimens. More information can be found on ADVENTRX's web site at http://www.adventrx.com.


'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. ADVENTRX Settles Dispute With Former Licensee
2. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
3. ADVENTRX Appoints Vice President of Manufacturing
4. ADVENTRX Creates Executive Vice President Position and Announces New Chief Financial Officer
5. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
6. ADVENTRX Pharmaceuticals to Report Fourth Quarter and Year End 2007 Results
7. Eric K. Rowinsky Joins ADVENTRX Board of Directors
8. ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting
9. ADVENTRX Announces Consolidation of Clinical and Management Positions
10. ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results
11. ADVENTRX Appoints Vice President of Commercialization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... Whitehouse Labs ... Within Albany Molecular Research, Inc. (AMRI), the scientific staff dedicated to Extractables / ... planned for further growth in 2017. Extractable & Leachable evaluations have become increasingly ...
(Date:1/18/2017)... Gainesville, FL (PRWEB) , ... January 18, 2017 ... ... muscle weakness and paralysis, today announced that it has submitted a 510(k) to ... stationary bikes that utilize MYOLYN’s patent-pending functional electrical stimulation (FES) technology. , ...
(Date:1/18/2017)... ... January 18, 2017 , ... DrugDev ... for Clinical Ops Executives (Hyatt Regency Miami, January 24-26). DrugDev will join customers ... research issues such as trial performance metrics, patient enrollment diversity, protocol optimization, and ...
(Date:1/18/2017)... ... January 18, 2017 , ... uBiome, ... latest paper by its Science Editor, Dr. Elisabeth Bik, in the December 2016 ... Dr. Bik joined uBiome in October 2016 from her previous position at Stanford ...
Breaking Biology Technology:
(Date:12/15/2016)... Calif. , Dec. 15, 2016   WaferGen ... publicly held genomics technology company, announced today that on ... Listing Qualifications Department of The Nasdaq Stock Market LLC ... closing bid price of WaferGen,s common stock had been ... Accordingly, WaferGen has regained compliance with Listing Rule 5550(a)(2) ...
(Date:12/15/2016)... , Dec. 14, 2016 "Increase in ... biometrics market" The mobile biometrics market is expected to ... 49.33 billion by 2022, at a CAGR of 29.3% ... factors such as the growing demand for smart devices, ... transactions. "Software component is expected to grow ...
(Date:12/7/2016)... According to a new market research report "Emotion Detection and Recognition Market ... Application Area, End User, And Region - Global Forecast to 2021", published by ... 2016 to USD 36.07 Billion by 2021, at a Compound Annual Growth Rate ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):